Drug Approval | November 27, 2025
The trial tested six injectable doses and three oral doses over as long as 36 weeks
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Surgical site infections and antimicrobial resistance remain major challenges globally
The State’s PPP model has already mobilised Rs. 150 crore in core infrastructure, while Thermo Fisher has invested Rs. 90 crore in the Bioprocess Design Centre and its co-located Customer Experience Centre
A key highlight will be Brenntag’s qualified amino acids portfolio
The new Bioprocess Design Center will serve as a cutting-edge scale-up hub for biologics and vaccine manufacturing
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
Globally, Abbott has received reports of 736 severe adverse events linked to the issue, including seven deaths (none in the US)
Subscribe To Our Newsletter & Stay Updated
